Lifecore Biomedical sets November 4 record date for merger vote

Lifecore Biomedical, Inc. has established November 4, 2026, as the record date for a special meeting of stockholders to approve the company's pending merger with Lifecore Inc. The Board of Directors made this determination on October 16, 2026, in connection with an Agreement and Plan of Merger originally signed on September 27, 2026.

The special meeting will allow stockholders of record as of the close of business on November 4 to receive notice and vote on the adoption of the Merger Agreement and the merger it contemplates. Lifecore Biomedical, a Delaware corporation headquartered in Chaska, Minnesota, filed the update with the Securities and Exchange Commission on Form 8-K. The company's common stock, which carries a par value of $0.001 per share, trades on The NASDAQ Global Select Market under the symbol LFCR.

In accordance with the Merger Agreement, Lifecore Biomedical intends to file both a preliminary and a definitive proxy statement with the SEC for the special meeting. The company advises investors to review these filings closely once they are available, as they contain material details about the transaction. Free copies of the proxy statement and related documents will be accessible through the SEC's website at www.sec.gov, the investor relations section of Lifecore Biomedical's website at https://ir.lifecore.com, or by calling (952) 368-4300.

The filing clarifies that this Form 8-K does not constitute a solicitation of a proxy or an offer to sell securities. However, the company, its directors, and executive officers may be deemed participants in the solicitation of proxies from stockholders in connection with the proposed merger. Information regarding the direct or indirect interests of these individuals in the transaction is detailed in the company's definitive proxy statement for its 2026 Annual Meeting of Stockholders, which was filed with the SEC on April 24, 2026.

Subsequent changes to beneficial ownership by directors or executive officers are or will be reflected in Form 3, Form 4, or Form 5 filings submitted to the SEC. These documents are available for free in the same manner described for the proxy statement. Ryan D. Lake, Chief Financial Officer of Lifecore Biomedical, signed the report on October 20, 2026.